A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

July 7, 2028

Study Completion Date

July 7, 2028

Conditions
Mantle Cell Lymphoma (MCL)
Interventions
DRUG

Acalabrutinib

Investigational Product

DRUG

Venetoclax

Investigator Product

DRUG

Rituximab

Investigator Product

Trial Locations (29)

2109

Research Site, Sydney

3084

Research Site, Heidelberg

6009

Research Site, Nedlands

11794

Research Site, Stony Brook

19104

Research Site, Philadelphia

28041

Research Site, Madrid

44195

Research Site, Cleveland

77030

Research Site, Houston

07601

Research Site, Hackensack

NSW 2217

Research Site, Kogarah

90035-003

Research Site, Porto Alegre

22061-080

Research Site, Rio de Janeiro

01401-002

Research Site, São Paulo

05403-010

Research Site, São Paulo

T6G 1Z2

Research Site, Edmonton

V5Z 4E6

Research Site, Vancouver

B3H 2Y9

Research Site, Halifax

L4M 6M2

Research Site, Barrie

M5G 2M9

Research Site, Toronto

H3T 1E2

Research Site, Montreal

81-519

Research Site, Gdynia

30-727

Research Site, Krakow

02-781

Research Site, Warsaw

B9 5SS

Research Site, Birmingham

GL1 3NN

Research Site, Gloucester

SW3 6JJ

Research Site, London

NR4 7UY

Research Site, Norwich

NG5 1PB

Research Site, Nottingham

PL68BQ

Research Site, Plymouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY